Skip to content
  • Print

Empowering Therapeutic Peptides by Enhancing its in vivo Half-Life

Mamoun AlhamadshehVideo is currently unavailable. Will be updated soon!!

The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmaco­kinetic profile, due to short in vivo half-life. Therefore, ex­tending the in vivo half-life of peptides is clearly desirable in order for their therapeutic potential to be realized, without the need for high doses and frequent administration. Our group is developing a novel strategy that will enhance the pharmacokinetic properties of thera­peutic peptides, which could decrease dosing frequency and im­prove patient convenience and compliance.

Mamoun AlhamadshehMamoun Alhamadsheh, Ph.D.
Dr. Alhamadsheh is an assistant professor in the School of Pharmacy at Pacific. He received his PhD in Organic Chemistry from the Univer­sity of Toledo and did his postdoctoral studies in Chemical Biology at Stanford University and Portland State University. His research group employs an interdisciplinary approach to studying protein-protein interac­tions (PPIs), combining organic chemistry with biochemistry and molecular biology. Dr. Alhamdsheh's group is particularly inter­ested in developing chemical tools and therapeutic agents for protein aggregation diseases such as Alzheimer's disease and Transthyretin Amyloidosis. Dr. Alhamadsheh is a recipient of New Investigator Award from AACP. He has co-authored three patents and 17 articles in peer-reviewed journals.